INTRODUCTION {#sec1}
============

Propionibacterium acnes is a facultative anaerobic Gram-positive bacterium present on human skin as part of the normal flora, as well as in the oral cavity, large intestine, conjunctiva, and external ear canal ([@B1]). P. acnes is the most prevalent bacterium in sebaceous areas of the skin ([@B2], [@B3]) but is also abundant in dry areas ([@B3]). P. acnes predominates in the pilosebaceous follicles of the skin ([@B4]).

P. acnes is proposed to play a role in the development of acne vulgaris ([@B5]) and is considered an opportunistic pathogen causing postoperative infections ([@B6]). It has been isolated from patients with endocarditis ([@B7]), synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome ([@B8]), and sarcoidosis ([@B9]), among other syndromes. Some studies also identify P. acnes to be a contaminant of blood products, tissue cultures, and surgical wounds ([@B10][@B11][@B13]), and the significance of this widely abundant skin commensal is consequently debated.

The postulated role of P. acnes in various conditions is often highly speculative and based on the mere detection of the bacterium ([@B8], [@B9], [@B14][@B15][@B19]). To expand the knowledge of the abundance of P. acnes, we investigated the proportions of P. acnes sequences in samples of a wide variety of cancer types, as well as blood samples. Next-generation sequencing was performed on DNA extracted either after enrichment for intact microbes or directly from the samples. This study is the first large-scale analysis investigating the abundance of P. acnes DNA in such diverse tissue types by next-generation sequencing, and we show that P. acnes can be readily detected in literally all sample types investigated, particularly when samples are subjected to microbial enrichment.

MATERIALS AND METHODS {#sec2}
=====================

Ethics statement. {#sec2-1}
-----------------

Human sample collection, handling, and analysis were performed under ethical protocol H-2-2012-FSP2 (Regional Committee on Health Research Ethics, Capital Region of Denmark) and case no. 1304226 (National Committee on Health Research Ethics, Denmark). In accordance with Danish national legislation (Sundhedsloven), all human samples were processed anonymously.

Patient samples. (i) Samples collected in Denmark. {#sec2-2}
--------------------------------------------------

Malignant melanoma biopsy specimens and cells from patients with acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia (B-CLL), and chronic myelogenous leukemia (CML) sorted by fluorescence-activated cell sorting (FACS) were obtained from Aarhus University Hospital. Samples from patients with T-lineage acute lymphoblastic leukemia (T-ALL) were obtained from either Aarhus University Hospital (cells sorted by FACS; *n* = 9) or Rigshospitalet (Copenhagen University Hospital; bone marrow samples; *n* = 2). Samples (bone marrow) from patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and biopsy specimens from patients with oropharyngeal or oral cavity head and neck cancer and testicular cancer were obtained from Rigshospitalet. Biopsy specimens from patients with basal cell carcinoma and mycosis fungoides (cutaneous T-cell lymphoma) were obtained from Bispebjerg Hospital. Bladder, breast, and colon cancer biopsy specimens, blood samples from colon cancer patients, and ascitic fluid samples from colon, ovarian, and pancreatic cancer patients were obtained from or collected in collaboration with the Danish Cancer Biobank, Herlev Hospital. Ascitic fluid samples were subjected to low-speed centrifugation upon receipt to pellet intact host cells and cellular debris. The supernatant was used for microbial enrichment, whereas pelleted cells were used for shotgun sequencing. Cryopreserved, fully transformed B-cell lymphoma cell lines (OCI Ly3_M, OCI-Ly7_M, OCI-Ly8, SU-DHL-4, SU-DHL-5, and U698M) and multiple myeloma cell lines (KMS-12-BM, KMS-12-PE, MOLP-2, MOLP-8, RPMI-8226, and U266) were obtained from Aalborg University Hospital.

(ii) Samples collected outside Denmark. {#sec2-3}
---------------------------------------

Vulva cancer biopsy specimens were obtained from the National Institute of Oncology, Budapest, Hungary. All samples are listed in [Table 1](#T1){ref-type="table"}.

###### 

Samples included in the study[^*a*^](#T1F1){ref-type="table-fn"}

  Disease                                         Abbreviation   Sample type                            No. of samples subjected to:   
  ----------------------------------------------- -------------- -------------------------------------- ------------------------------ -----
  Acute myeloid leukemia                          AML            Bone marrow (sorted cells)             9                              
  B-cell chronic lymphocytic leukemia             B-CLL          Blood/bone marrow (sorted cells)       9                              
  B-cell precursor acute lymphoblastic leukemia   BCP-ALL        Bone marrow                            8                              
  Basal cell carcinoma                            BCC            Tumor biopsy specimens                 11                             11
  Bladder cancer                                                 Tumor biopsy specimens                 7                              
  Breast cancer (ductal/lobular)                                 Tumor biopsy specimens                 17                             20
                                                                 Ascitic fluid                          1                              1
  Chronic myelogenous leukemia                    CML            Bone marrow (sorted cells)             10                             
  Colon cancer                                                   Tumor biopsy specimens                 3                              12
                                                                 Blood                                                                 8
                                                                 Ascitic fluid                                                         1
  Lymphoma/myeloma                                               Cell lines                                                            12
  Malignant melanoma                                             Tumor biopsy specimens                 10                             10
  Mycosis fungoides (cutaneous T-cell lymphoma)   Mycosis        Tumor biopsy specimens                 11                             11
  Oropharyngeal/oral cavity cancer                Oral           Tumor biopsy specimens                 10                             9
  Ovarian cancer                                                 Ascitic fluid                          3                              5
  Pancreatic cancer                                              Ascitic fluid                                                         2
  T-lineage acute lymphoblastic leukemia          T-ALL          Bone marrow (nonsorted/sorted cells)   11                             
  Testicular cancer (sem/non-sem)                 Testis         Tumor biopsy specimens                 20                             5
  Vulva cancer                                    Vulva          Tumor biopsy specimens                 3                              
  Total no. of sample types and samples                          20                                     143                            107

The diseases, sample types, and number of samples included are shown.

Laboratory facilities. {#sec2-4}
----------------------

All sample processing was performed under conditions designed to diminish contamination through the use of a unidirectional work flow. Separate laboratories were used for reagent preparation, sample extraction and sequencing library preparation, and library amplification. All laboratory work was conducted by individuals who were wearing a lab coat and gloves, as well as sleeves during extraction and library preparation. All sample processing was carried out in laminar-flow cabinets equipped with UV lamps. All benchtops were cleaned with 5% bleach and 70% ethanol before and after any lab work. Only sterile, disposable lab utensils were used. Filter tips were used for all pipetting.

Microbial enrichment, nucleic acid extraction, and library preparation. {#sec2-5}
-----------------------------------------------------------------------

Samples used for enrichment were fresh frozen after collection, and no nucleic acid preservatives were added. Each batch of processed samples included a nontemplate control containing only phosphate-buffered saline (PBS), which was run in parallel with the patient samples (*n* = 19). Samples were kept on ice unless otherwise stated.

Biopsy specimens were thawed and transferred to 400 μl cold PBS. For the samples from leukemia patients, 150 to 400 μl was mixed with cold PBS to a total volume of 400 μl. Two stainless steel beads of 2 to 3 mm in diameter were added to the samples, which were subsequently homogenized using a TissueLyser II tissue disrupter (Qiagen, Hilden, Germany) for 6 min at 30 Hz. All tissue homogenates, samples from leukemia patients, and ascitic fluid specimens (1 ml) devoid of pelleted cells were centrifuged for 2 min at 800 × *g* to remove tissue debris, and the supernatants were subsequently filtered through 5-μm-pore-size centrifuge filters (Millipore, Darmstadt, Germany). To remove unprotected nucleic acids while retaining the nucleic acids within bacterial cells or viral particles, the filtrates were nuclease digested using 14 μl Turbo DNase (2 U/μl; Ambion, Thermo Fisher Scientific, Waltham, MA, USA), 12 μl Baseline-Zero DNase (1 U/μl; Epicentre, Madison, WI, USA), 16 μl RNase cocktail enzyme mix (Ambion), and 40 μl 10× Turbo DNase buffer in a total volume of 400 μl and incubated at 37°C for 2 h. Nucleic acids from the enriched samples were extracted using the High Pure viral RNA kit (Roche, Basel, Switzerland) according to the manufacturer\'s instructions with the addition of 10 μg linear acrylamide carrier (Applied Biosystems, Foster City, CA, USA).

DNA libraries were built using the Nextera or Nextera XT DNA sample preparation kit (Illumina, San Diego, CA, USA), according to the manufacturer\'s instructions. Nextera libraries were amplified by 20 cycles of PCR, and Nextera XT libraries were amplified by 12 cycles of PCR. The amplified and indexed libraries were purified using the Agencourt AMPure XP PCR purification system (Beckman Coulter, Indianapolis, IN, USA). In case of insufficient amplification, libraries were reamplified using AccuPrime *Pfx* DNA polymerase (Life Technologies, Carlsbad, CA, USA) and P5 and P7 sequence primers.

Total DNA extraction and library preparation. {#sec2-6}
---------------------------------------------

Total DNA was extracted from samples using the QIAamp DNA minikit (Qiagen) following the manufacturer\'s instructions. DNA libraries were prepared from 1 μg of DNA using either the TruSeq DNA protocol (catalog number PE-940-2001; Illumina, San Diego, CA, USA) or an in-house protocol ([@B20]) using NEBnext reagents (protocol E6070; New England BioLabs, Ipswich, MA, USA).

Sequencing. {#sec2-7}
-----------

Paired-end sequencing (2 reads of 100 bp) was performed on the Illumina HiSeq 2000 platform at BGI-Europe (Copenhagen N, Denmark).

Analysis of sequence data. (i) Preprocessing and depletion of human sequence reads. {#sec2-8}
-----------------------------------------------------------------------------------

Paired-end sequencing reads were trimmed of adapter sequences, and overlapping read pairs were merged using AdapterRemoval software (version 1.5.3) ([@B21]). Reads shorter than 30 nucleotides after trimming were excluded from further analysis. For digital subtraction of human sequence reads, the remaining reads were mapped to the human genome (hg38) using the mem algorithm implemented in Burrows-Wheeler Aligner (BWA; version 0.7.7) ([@B22]). Reads of a pair were evaluated independently. Reads containing 25 bp or more of low-complexity regions were filtered out using the DustMasker algorithm (version 1.0.0) ([@B23]).

(ii) Analysis of reads mapping to P. acnes. {#sec2-9}
-------------------------------------------

Genomic sequences from 97 P. acnes strains representing complete genomes, scaffolds, or contigs were downloaded from the NCBI genome resource (<http://www.ncbi.nlm.nih.gov/genome/genomes/1140>) (see Table S1 in the supplemental material). Reads filtered of human and low-complexity sequences were mapped to the P. acnes sequences using the aln algorithm in BWA ([@B22]) after duplicate reads had been marked using the SAMBLASTER program ([@B24]). Only reads with a perfect match were kept for further analysis. The proportion of P. acnes reads was calculated as the number (parts per million) of unique P. acnes reads relative to the total number of demultiplexed reads.

(iii) Analysis of the P. acnes strains present. {#sec2-10}
-----------------------------------------------

The presence of the different P. acnes strains was assessed on the basis of the mapping to the P. acnes genomic sequences (above). Only reads mapping exclusively to a single strain were considered for this analysis. Information regarding the phylogenetic type of the different strains was obtained from the P. acnes multilocus sequence typing (MLST) database (<http://pubmlst.org/pacnes/>).

(iv) Analysis of the coverage of the P. acnes genome. {#sec2-11}
-----------------------------------------------------

To visualize the genomic coverage of P. acnes, all nonhuman reads were mapped to the 12 full P. acnes genomes currently present in GenBank using the mem algorithm implemented in BWA (version 0.7.7) ([@B22]). The resulting alignments are represented as Circos plots ([@B25]).

Nucleotide sequence accession numbers. {#sec2-12}
--------------------------------------

Sequencing reads mapping to P. acnes have been uploaded to the European Nucleotide Archive (ENA) and are available under accession number [PRJEB12636](http://www.ebi.ac.uk/ena/data/view/PRJEB12636).

RESULTS {#sec3}
=======

P. acnes in microbe-enriched and shotgun-sequenced samples. {#sec3-1}
-----------------------------------------------------------

The relative number of P. acnes sequencing reads in 180 samples of 20 different sample types was analyzed ([Table 1](#T1){ref-type="table"}). Ascitic fluid samples and lymphoma/myeloma cell lines were analyzed as each being one common sample category. One hundred forty-three samples were processed to enrich for intact microbes before extraction of DNA and preparation of sequencing libraries. Sequencing reads from which human reads were removed were mapped to a custom database containing the 97 P. acnes genomes currently present in GenBank as full genomes or genome assemblies. P. acnes levels were assessed as the number (parts per million) of unique P. acnes reads relative to the total number of demultiplexed reads (see Materials and Methods). Using this approach, we detected relative levels of P. acnes reads exceeding 300 ppm in samples from patients with basal cell carcinoma (median, 576 ppm), mycosis fungoides (median, 480 ppm), malignant melanoma (median, 446 ppm), and breast cancer (median, 373 ppm) ([Fig. 1](#F1){ref-type="fig"}, black bars; see also Table S2 in the supplemental material). The proportions of P. acnes reads detected in the remaining enriched samples were below 100 ppm (median, 0.8 to 89 ppm). P. acnes reads were also detected in nontemplate control samples containing PBS run in parallel with the enriched samples (*n* = 19). In these samples, the relative proportion of P. acnes reads was high (median, 10,377 ppm) (see Discussion).

![Relative P. acnes levels in enriched (black bars) and shotgun-sequenced (gray bars) samples having a median P. acnes proportion of \>1 ppm. The proportions of unique P. acnes reads (in parts per million) organized according to tissue type are shown on a logarithmic scale. The error bars indicate 1 standard deviation. BCC, basal cell carcinoma; Subcut., subcutaneous.](zjm9990948680001){#F1}

Total DNA extracted from 107 samples was subjected to shotgun sequencing ([Table 1](#T1){ref-type="table"}). Only samples from patients with basal cell carcinoma (median, 3.9 ppm), malignant melanoma (median, 1.2 ppm), and breast cancer (median, 1.1 ppm) contained relative P. acnes levels above 1 ppm ([Fig. 1](#F1){ref-type="fig"}, gray bars; see also Table S2 in the supplemental material). The fold increase in the median number of P. acnes reads (parts per million) in enriched samples relative to the number in shotgun-sequenced samples ranged from 35 in colon cancer biopsy specimens (12 versus 0.3 ppm) to \>1,000 in samples from patients with mycosis fungoides (480 versus 0.5 ppm). The blood samples contained the lowest relative P. acnes levels of all samples included in this study (median, 0.05 ppm).

Distribution of P. acnes strains. {#sec3-2}
---------------------------------

To assess the P. acnes strains and the phylogenetic groups present in our samples, we analyzed the distribution of reads mapping to the 97 P. acnes genomes used in our analysis. Only reads mapping unambiguously to one P. acnes strain were included in the analysis. Using this criterion, an average of 8.6% of the P. acnes reads were included in the analysis (see Table S3 in the supplemental material); however, with this approach we ensured a high stringency when assigning the reads. [Figure 2](#F2){ref-type="fig"} shows the relative abundance of strains for each sample. The phylogenetic type is indicated next to the individual strain names. For 20 of the strains included, the phylogenetic type was not determined, and these are designated unknown (Unkn.). Overall, two strains predominated across samples for both enriched and shotgun-sequenced samples ([Table 2](#T2){ref-type="table"}; see also Table S4 in the supplemental material), namely, strains 119_PAVI and SK182B-JCVI (both of unknown phylogenetic type). Strains HL025PA1 and HL050PA2 (type IA~1~ and type II, respectively) were also among the 10 most abundant strains detected by both methods. Certain strains, such as JCM 18920 (unknown type), HL001PA1 (type II), and C1 (type IA~1~), were mainly detected in enriched samples, while other strains, such as HL110PA4 (type II) and HL411PA1 (unknown type), were mainly detected in shotgun-sequenced samples.

![Relative distribution of P. acnes strains in the individual samples. The *y* axis shows the percentage accounted for by each strain, and each vertical line represents a sample. The bottom horizontal lines indicate enriched or shotgun-sequenced samples, and the bottom vertical ticks delimit the sample categories. The phylogenetic type of the P. acnes strains is indicated next to the strain name in the key on the right. The strains mentioned in the main text are highlighted in bold. NTC, nontemplate control; Unkn., unknown.](zjm9990948680002){#F2}

###### 

Prevalence of the 20 most frequently detected P. acnes strains in samples investigated by microbial enrichment, shotgun sequencing, and all samples combined

  Strain        Prevalence (%) in:        
  ------------- -------------------- ---- ----
  119_PAVI      82                   83   64
  SK182B-JCVI   78                   81   60
  HL025PA1      56                   62   36
  JCM 18920     45                   66   6
  HL050PA2      44                   52   23
  HL001PA1      34                   51   4
  HL411PA1      32                   26   36
  C1            31                   46   3
  HL110PA4      29                   14   46
  ATCC 6919     27                   32   14
  JCM 18909     26                   37   4
  HL082PA2      24                   35   
  J165          24                   22   22
  HL201PA1      20                   29   
  HL110PA1      19                        27
  HL030PA1      16                        21
  SK187         15                   22   
  HL099PA1      15                   21   
  HL078PA1      12                   18   
  J139          11                   15   4
  HL087PA2                           15   
  KPA171202                          14   
  HL056PA1                                7
  HL110PA3                                6
  HL025PA2                                4
  HL046PA2                                3
  HL074PA1                                3

Generally, greater strain diversity was seen in enriched tissue samples ([Fig. 2](#F2){ref-type="fig"}, left, indicated by the striated pattern seen for those samples; see also Fig. S1 in the supplemental material) than in shotgun-sequenced samples, ranging from an average of 10 different strains in samples from patients with testicular cancer to an average of 29 different strains in samples from patients with mycosis fungoides. The remaining samples contained an average of 2 to 9 different strains.

Coverage of the P. acnes genome. {#sec3-3}
--------------------------------

To evaluate the genomic coverage of P. acnes, nonhuman sequencing reads mapping to the 12 full genomes were presented using the Circos program (see Fig. S2 at [http://www.cbs.dtu.dk/∼txema/Supplementary/propioni_web/index.html](http://www.cbs.dtu.dk/~txema/Supplementary/propioni_web/index.html)). The plots show evenly distributed sequencing reads leading to almost full coverage of the P. acnes genome in some samples, whereas more sporadic coverage was seen in samples containing lower P. acnes levels. A disproportionately high sequencing depth was seen in two or three regions, depending on which reference genome was used for mapping, corresponding to the regions containing the genes encoding the rRNAs. The high depth of sequencing could be a result of reads originating from bacteria other than P. acnes mapping to the rRNA regions as a result of high sequence similarity between different bacterial rRNAs, as the algorithm used for generating the plots allows some mismatches, unlike the more stringent mapping algorithm used for quantification. To investigate if an excess of reads in the rRNA regions impacted the quantitative proportions of P. acnes, we reanalyzed these data by excluding reads mapping to the rRNA regions. For the majority of the samples, the reanalyzed values of the median relative levels of unique P. acnes reads were \<1% lower than the values presented above, except for some sample types containing very low numbers of P. acnes reads (see Table S2 in the supplemental material). These results indicate that an excess of reads mapping to rRNA regions generally was not found in our quantification analysis.

DISCUSSION {#sec4}
==========

During metagenomic analysis of next-generation sequencing data from patient samples, we identified considerable amounts of genetic material from the bacterium P. acnes. P. acnes is known to contaminate human samples, and this initial discovery therefore prompted us to investigate the abundance of P. acnes in metagenomic data from a range of different human clinical samples. In the present study, we investigated the proportions of P. acnes DNA in data from samples subjected to enrichment for intact microbes and from samples subjected to shotgun sequencing of the total pool of DNA. We detected the highest relative levels of P. acnes in samples subjected to enrichment, with relative P. acnes levels being the highest in skin tissue-derived samples and breast cancer biopsy specimens ([Fig. 1](#F1){ref-type="fig"}). Basal cell carcinoma samples contained the highest P. acnes levels among the shotgun-sequenced samples, while most other shotgun-sequenced samples as well as enriched samples from patients with BCP-ALL contained P. acnes at levels below 1 ppm (see Table S2 in the supplemental material).

Prior to surgical procedures or penetration of the skin for sampling of blood, the skin is routinely sterilized using antiseptics. However, antiseptic preparation of the skin does not kill all bacteria or affect bacteria present in the deeper layers of the skin ([@B26], [@B27]), and bacteria from surrounding areas of the skin may rapidly recolonize the antiseptically treated areas ([@B28], [@B29]). Moreover, antiseptics do not remove extracellular bacterial DNA present on the skin. Therefore, detection of P. acnes in skin tissue samples is not unexpected. As the breast tissue lies just beneath the subcutaneous adipose tissue in an area of the skin rich in P. acnes, contamination from the skin during surgery is conceivable.

In our study, microbial enrichment was achieved by reducing the amount of host endogenous DNA by centrifugation and filtration followed by nuclease treatment of fluid samples or tissue homogenates. This procedure is widely used for enrichment of intact viral particles in virus discovery studies ([@B30][@B31][@B33]) and results in an increase in the amount of intact viral nucleic acids relative to the amount of host nucleic acids ([@B34]). We did not culture bacteria from the samples, and therefore, we do not know if the detected bacterial DNA originated from live bacteria capable of forming colonies. As the DNA of live bacteria is protected from degradation by DNases ([@B35], [@B36]), the up to \>1,000-fold increase in the median proportion of P. acnes reads achieved upon enrichment could suggest that the P. acnes DNA detected in our samples at least partially originated from live bacteria.

Over the years, P. acnes has been detected in samples from patients with diverse diseases, which has led to its proposed association with several conditions. Among these, P. acnes has been implicated in the pathogenesis of acne vulgaris, although its role in this condition is still debated ([@B37]). Other diseases for which the bacterium is proposed to play a role are sarcoidosis ([@B9]), diverse spine conditions ([@B15][@B16][@B17]), SAPHO syndrome ([@B8]), aortic aneurysms ([@B18]), and prostate cancer ([@B19]). Common to these studies is that detection of P. acnes is based on culture, PCR, or a combination of the two. In most of the studies, roughly half of the samples are positive, and the identified bacterium is P. acnes in about half of the cases. Besides the proposed role in certain diseases and syndromes, P. acnes is considered a contaminant of blood products ([@B11], [@B38]), surgical wounds ([@B12], [@B39]), and heart valve tissue cultures used in the diagnosis of infection during valve replacement surgery ([@B10]). The fact that P. acnes is often detected at similar frequencies in surgical wounds and samples from patients with various diseases could imply that the detection of P. acnes is incidental as a result of its widespread presence. Studies investigating the role of P. acnes or other ubiquitous bacteria in infections or diseases should therefore be designed to allow researchers to distinguish between contamination and true infection. Approaches suggested to help distinguish between these include the performance of multiple cultures ([@B11]), histopathological analysis ([@B7]), distinguishing of single bacterial cells from biofilm-related infections by immunofluorescence microscopy ([@B12]), and investigation of the ability of P. acnes isolates to form biofilm ([@B40]). The invasiveness of P. acnes isolates may also hint to a possible disease-causing role of P. acnes in some cases ([@B41]). MLST schemes have revealed three major phylogenetic groups of P. acnes, types I, II, and III ([@B42], [@B43]), with type I being further divided into types IA~1~, IA~2~, IB, and IC. Clustering analysis found acne vulgaris to be predominantly associated with certain clonal complexes within type IA~1~, while types IB and II were more frequently recovered from soft tissue and retrieved medical devices. Certain P. acnes sequence types from types II and III were recovered only from healthy skin ([@B44]).

In our samples, recurring P. acnes strains predominated across sample types, including in the nontemplate controls (see Table S4 in the supplemental material). Two of these strains were also ubiquitously detected in skin microbiomes ([@B3]). These findings could suggest that some strains are widespread among individuals or that they arise from reagent or lab contamination, as P. acnes or propionibacteria are well-known contaminants of next-generation sequencing data ([@B45][@B46][@B47]). Our nontemplate controls containing PBS run in parallel with the enriched samples contained high relative levels of P. acnes. This could occur as a result of cross-contamination during sample processing, contamination from lab personnel or the reagents used, or bleeding over from libraries with high P. acnes levels sequenced on the same lanes of the flow cell ([@B34], [@B48]). With the exception of two, all the nontemplate control libraries contained DNA at levels below the detection limit of both the Qubit and Bioanalyzer instruments (data not shown), but the libraries were nevertheless sequenced. Comparison of the nontemplate control data sets to the data sets for the other enriched samples showed that the controls contained an average of 12% human reads, while the biological samples contained an average of 91% human reads (see Table S2 in the supplemental material). This dissimilar composition of the data sets suggests that the sequence reads in the controls, including the P. acnes reads, did not mainly originate from cross contamination or bleeding over. Studies investigating contamination in next-generation sequencing data show that more dilute samples contain higher fractions of contaminating reads ([@B46], [@B47]) and that negative controls contain reads mapping to a variety of bacterial genera, including propionibacteria ([@B47]). This could be explained by the more extensive PCR amplification of contaminant templates from samples containing nearly no DNA than of the same amount of contaminant templates from complex samples containing human DNA as well competing for the same quantity of primers and other PCR reagents. Considering this skewed amplification and the circumstance that the biological data sets are diluted with a large amount of endogenous human reads, the relative level of P. acnes reads in the controls becomes less astounding. The detection of P. acnes in the controls can thus be interpreted as further evidence of how easily samples are contaminated with this ubiquitous bacterium, regardless of the source.

We believe that the high relative P. acnes levels detected, particularly in enriched skin tissue and breast cancer biopsy samples, reflect patient-derived contamination. Similar patterns showing traces of P. acnes in most sample types and higher levels in samples from P. acnes-rich body sites have been seen in other microbiome studies ([@B49]). Our hypothesis is supported by the high diversity of P. acnes strains seen in these samples compared to the low diversity seen in other samples, including the controls (see Fig. S1 in the supplemental material). The low strain diversity in the controls supports the hypothesis that overamplification occurs in these samples. More adequate negative controls for P. acnes levels in our study were the blood samples from colon cancer patients, as these are, in principle, sterile samples containing high levels of endogenous DNA. In these samples, we detected practically no P. acnes reads (median, 5 in absolute numbers, or 0.05 ppm; see Table S2 in the supplemental material).

Considering our findings, it is possible that contamination derived from the patient, the hospital personnel, or the lab personnel or that arises during sample processing and analysis contributes to the presence of P. acnes DNA in samples processed in clinical and molecular laboratories. The risk of contamination should therefore be considered carefully when interpreting molecular and sequencing data showing the presence of P. acnes, and negative controls should always be included. Typing of P. acnes can be a relevant tool when tracing the origin of P. acnes, but it does not necessarily provide clinically relevant information, as presumed cutaneous P. acnes strains are readily detected in diverse sample types. Efforts should be made to exclude the possibility that P. acnes originates from contamination and, importantly, to prove the causal relationship between this bacterium and the disease in question.

Supplementary Material
======================

###### Supplemental material

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JCM.02723-15>.
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